top of page

Clinical Research

We offer hope to those with retinal diseases by providing access to clinical trials that could potentially improve their condition and advance treatment outcomes for future patients

(925) 265-4146

Current Clinical Trials

Diabetic Macular Edema (DME)

Diabetic Retinopathy (DR)

Geographic Atrophy (GA)

Intermediate Age-Related Macular Degeneration (iAMD)

Macular Telangiectasia (MacTel)

Retinitis Pigmentosa (RP)

Wet Age-Related Macular Degeneration (wAMD)

Diabetic Macular Edema (DME)

THULITE

Boehringer Ingelheim

A Phase 2 randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema for 48 weeks of treatment

THAMES

Genentech

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination with Aflibercept or Faricimab in Patients with Diabetic Macular Edema

CAPRI

EyePoint Pharmaceuticals

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (DME)
To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy, and willing to allow Aqueous Humor collection

PREGONDA

Roche

A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participation with Diabetic Macular Edema

Diabetic Retinopathy (DR)

NAAVIGATE

AbbVie Inc.

A Phase 2b/3 study evaluating the safety and efficacy of surabgene lomparvovec (sura-vec, formerly ABBV-RGX-314) gene therapy in treating diabetic retinopathy (DR)

CRIMSON

Boehringer Ingelheim

A Phase 2b clinical trial evaluating BI 764524, an anti-Sema3A antibody, for treating diabetic retinopathy

Minutes, Bay Area Retina Assoc, 4-24-26

Geographic Atrophy (GA)

ARCHER II

Annexon

A Phase 3 Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)

ReNEW

StealthBio Therapeutics

ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

JADE

Boehringer Ingelheim

Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of oral BI 1584862

VERDANT

Boehringer Ingelheim

A Phase 2 Randomized, double-masked, active-controlled, multicenter study to evaluate efficacy and safety of two regimens of intravitreal BI 771716 against pegcetacoplan in participants with geographic atrophy secondary to age-related macular degeneration

GARLAND

Apellis Pharmaceuticals, Inc

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World
Safety, Tolerability and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with
Geographic Atrophy Secondary to Age-Related Macular Degeneration

GALLOP

Apellis Pharmaceuticals, Inc

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

PARASOL

Janssen

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

eDREAM

Galimedix Therapeutics, Inc.

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD (eDREAM)

Intermediate Age-Related Macular Degeneration (iAMD)

HONU

Genentech

Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related

Macular Telangiectasia (MacTel)

NHOR

The Lowy Medical Research Institute

The Natural History Observation Registry (NHOR) is a world-wide registry of individuals with Macular Telangiectasia type 2, and their family members.

NTMT-04

Neurotech Pharmaceuticals

Phase 4 Study: Long-term Safety and Efficacy of NT-501 (ENCELTO) CNTF Implant in MacTel Type 2, Including Sham Procedure Participants

Retinitis Pigmentosa (RP)

jCyte, Inc.

JC02-88 Stem Cell Treatment

Phase 2 Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa

Wet Age-Related Macular Degeneration (wAMD)

SOL

Ocular Therapeutix

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

ASCENT

AbbVie Inc.

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

PROTOCOL AO

DRCR

This study compares Home OCT-Guided Treatment versus Treat and Extend for the management of neovascular (wet) AMD.

4FRONT-2

4D Molecular Therapeutics

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 Gene Therapy in Adults with Macular Neovascularization

AQUARIUS

Adverum Biotechnologies, Inc.

A Phase 3 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) Gene Therapy in Participants With wet AMD

LUGANO

EyePoint Pharmaceuticals

A Phase 3 Study of EYP-1901 (Tyrosine Kinase Inhibitor) in Subjects With Wet Age-Related Macular Degeneration (wAMD)

LUCIA

EyePoint Pharmaceuticals

A Phase 3 Study of EYP-1901 (Tyrosine Kinase Inhibitor) in Subjects With Wet Age-Related Macular Degeneration (wAMD)

Minutes, Bay Area Retina Assoc, 2-9-26[9].docx

DME

GA

iAMD

MacTel

wAMD

Closed Trials

Retinitis Pigmentosa

DR

AERIE

ALTISSIMO

AVANTE

BHAM

ALEXION ONWARD

ARCHWAY

AVENUE

BI GA

ALLUVIUM

ASPIRE

BARDENAS

BOULEVARD

DERBY

GALE

NTMT-03

PREGONDA

DRCR

GALLEGO

OMASPECT

RAVEN

FOCUS

KINGFISHER

PANDA

RHINE

RHONE-X

SPECTRI

SUSHI

RIVOLI

STAIRWAY

TOFU

SAPPHIRE

STAMP

VAPOR

bottom of page